Pediatric blood & cancer · 2007
Validation of the oral mucositis assessment scale in pediatric cancer.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sung Lillian, Tomlinson George A, Greenberg Mark L, Koren Gideon, Judd Peter, Ota Sylvia, Feldman Brian M
Аннотация
BACKGROUND: Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy.
METHODS: Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration.
RESULTS: Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003).
CONCLUSIONS: The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.
METHODS: Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration.
RESULTS: Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003).
CONCLUSIONS: The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.
Предметные рубрики MeSH
Administration, OralAdministration, TopicalAdolescentAnalgesics, Non-NarcoticAntineoplastic Combined Chemotherapy ProtocolsChildDeglutition DisordersDoxorubicinErythemaFemaleFluid TherapyGingivitis, Necrotizing UlcerativeHumansMaleNarcoticsNeoplasmsOntarioPain MeasurementParenteral Nutrition, TotalSeverity of Illness IndexStomatitis